ALKS Alkermes plc

57.94
-0.31  -1%
Previous Close 58.25
Open 58.68
Price To book 7.33
Market Cap 8.88B
Shares 153,190,000
Volume 937,507
Short Ratio 7.71
Av. Daily Volume 850,133

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial initiated February 2016. Data due mid-2018.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option PDUFA date June 5, 2017.
Aristada
Schizophrenia
Phase 3 initiation announced March 16, 2017. NDA filing due 2018.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2H 2017.
ALKS 5461
Major depressive disorder
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Pivotal trial initiated December 2015. Completion of enrollment announced May 1, 2017. Data due mid-2017.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia

Latest News

  1. Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017
  2. Why These Drug Stocks May Surge
  3. Big Week Ahead for Alkermes
  4. Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting
  5. 3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018
  6. [$$] Three Top Picks in Smaller Pharma
  7. Blog Coverage Alkermes Announces Completion of Patient Enrolment in ALKS 3831 Study for the Treatment of Schizophrenia
  8. Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo
  9. ETFs with exposure to Alkermes Plc : May 1, 2017
  10. Alkermes' Revenue Jumps 22%
  11. Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 1, 2017
  12. Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia
  13. Edited Transcript of ALKS earnings conference call or presentation 27-Apr-17 12:30pm GMT
  14. Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
  15. Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss
  16. Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
  17. Alkermes reports 1Q loss
  18. Biotech Earnings Roundup: Exact Sciences Flying Higher
  19. Alkermes plc Reports First Quarter 2017 Financial Results
  20. Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference